| Management target | Revenue FY28 |
|---|
| Revenue growth | 13% YoY consolidated growth. |
|---|---|
| Margins | Steady gross margin profile expected at 58%-60%. |
| Demand visibility | Strong funnel in UK, Nordics, and Africa. |
| Management confidence | High in Ex-US growth and diversified strategy. |
Growth
Revenue up 13% YoY; Ex-US markets grew 17%. Gross margins improved 14% YoY to 60.9%.
Outlook
Aspirational North America revenue of ~$375m by FY28; focus on nasal sprays and transdermal patches.
Risks
Geopolitical disruptions impacted freight costs by ~₹131m; slower US quota allocations affecting controlled substances.
Last quarter's promises, checked
Delivered
- Gross margins 58%-60% → delivered 60.9% (= BEAT)
- EBITDA margins ~19% → delivered 19.3% (= BEAT)
- Net Debt/EBITDA 1.55x → delivered 1.52x (= BEAT)
Partly delivered
- Sequential Q-on-Q growth → delivered 13% YoY but US growth only 4% (= PARTIAL)
Missed
- US revenue $375m-$400m target → delivered $284m FY26 (= MISS)
Investor Presentation filed with NSE, NSE: STAR. Summary written with AI assistance from the document.
Strides Pharma Science Ltd: key numbers
- Share price
- ₹1,184.90
- Market cap
- ₹10,922 Cr
- Revenue (annual)
- ₹4,859 Cr
- Net profit (annual)
- ₹556.2 Cr
- P/E (TTM)
- 17.8×Sector 50.4×
- Promoter holding
- 27.91%+0.00% QoQ
- FII holding
- 28.40%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Strides Pharma Science Ltd
All →Strides Pharma Science Business Update
Strides Pharma Science received a Form 483 with three observations following a routine USFDA inspection at its Alathur formulations facility. The company will respond within stipulated timelines.
Strides Pharma Science Earnings Call Transcript: Key Takeaways
Strides Pharma Science reported Q1 FY27 results with 13% YoY revenue growth and EBITDA margins maintained at 18.2%. Strategy focuses on Ex-US growth and US portfolio diversification.
- Call
- Guides 32% growth
Strides Pharma Science Q1 FY27 Results: Net Profit ₹165.5 Cr, Up 56.7% YoY
Strides Pharma Science Ltd reported revenue from operations of ₹1,265 Cr (+13.0% YoY) and net profit of ₹165.5 Cr (+56.7% YoY) for Q1 FY27.
- Key figure
- Net profit ₹165.5 Cr · +56.7% YoY
Strides Pharma Science Earnings Call: Key Takeaways
Strides Pharma reported its highest ever EBITDA and operational PAT for FY26, driven by significant geographical diversification and a structural shift toward non-U.S. markets.
Strides Pharma Science Earnings Call: Key Takeaways
Strides delivered strong FY26 performance with Revenue at ₹48,587m, up 6.4%, and Operational PAT at ₹5,181m, growing 50% YoY driven by Ex-US market efficiency.
Strides Pharma Science Q4 FY26 Results: Net Profit ₹129.3 Cr, Up 51.1% YoY
Strides Pharma Science Ltd reported revenue from operations of ₹1,324 Cr (+11.2% YoY) and net profit of ₹129.3 Cr (+51.1% YoY) for Q4 FY26.
- Key figure
- Net profit ₹129.3 Cr · +51.1% YoY